ABGX Abgenix (MM)

First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal Cancer THOUSAND OAKS, Calif. and FREMONT, Calif., Nov. 3 /PRNewswire-FirstCall/ -- - Amgen (NASDAQ:AMGN) and Abgenix, Inc. (NASDAQ:ABGX) today announced that a pivotal Phase 3 study of panitumumab met the primary endpoint of improving progression-free survival in patients with metastatic colorectal cancer (mCRC) who had failed standard chemotherapy. In this randomized Phase 3 trial involving 463 patients, those who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone (p